“Early treatment made possible by more sensitive diagnostic methods is expected to improve patient survival and significantly reduce the management costs for transplant patients.”
Dr. Dan Hauzenberger MD, PhD, Karolinska University Hospital, Stockholm, Sweden
Knowledge is power
Ignorance should never be a cause of relapse in stem cell transplant patients. Post-transplant chimerism monitoring enables close evaluation of donor engraftment, rapid detection of graft rejection, and measurable/minimal residual disease.
Post-transplant monitoring using sensitive diagnostic tests offers invaluable insight when evaluating patient recovery. Regular testing maximizes the potential for post-operative success and enhances the patient quality of life.
What’s our role?
We provide highly accurate and trusted chimerism test solutions that enable labs to quickly detect relapse and the potential presence of residual disease.
Our kits are custom-built to help physicians create the best conditions for successful patient outcomes and to streamline lab operations with a fast, smooth workflow.
Fast. Sensitive. Accurate.
Devyser’s single-protocol solutions offer fast, sensitive, and reliable chimerism measurement and monitoring in transplanted patients.
Our test kits use embedded software to perform rapid and precise measurements, making it easy to track a patient’s trends and detect relapse or micro chimerism at an early stage.
For lab users, this one-stop-shop approach saves valuable time, minimizes errors and maximizes productivity. Our tests are extremely accurate, with a standard deviation of 0.05 percent.
Insight and inspiration
News | January 17, 2024
Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first commercial agreement with UK based diagnostics company Cyted.Find out more
News | January 15, 2024Devyser wins tender for cystic fibrosis in Italy
News | Jan 08, 2024Devyser signs in vitro diagnostic agreement with Illumina to broaden access to its tests
News | December 12, 2023Devyser wins tender for non-invasive fetal RHD testing in Wales
Latest from the Devyser blogView all
Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvals
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS products
Collaboration and distribution agreement with Thermo Fisher Scientific Thermo Fisher Scientific...